RT Journal Article SR Electronic T1 Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.06.29.20139691 DO 10.1101/2020.06.29.20139691 A1 Liis Leitsalu A1 Marili Palover A1 Timo Tõnis Sikka A1 Anu Reigo A1 Mart Kals A1 Kalle Pärn A1 Tiit Nikopensius A1 Tõnu Esko A1 Andres Metspalu A1 Peeter Padrik A1 Neeme Tõnisson YR 2020 UL http://medrxiv.org/content/early/2020/06/30/2020.06.29.20139691.abstract AB Genotype-first approach allows to systematically identify carriers of pathogenic variants in BRCA1/2 genes conferring a high risk of familial breast and ovarian cancer. Participants of the Estonian biobank have expressed support for the disclosure of clinically significant findings. With an Estonian biobank cohort, we applied a genotype-first approach, contacted carriers and offered return of results with genetic counseling. We evaluated participants’ responses to and the clinical utility of the reporting of actionable genetic findings. Twenty-two of 40 contacted carriers of 17 pathogenic BRCA1/2 variants responded and chose to receive results. Eight of these 22 participants qualified for high-risk assessment based on National Comprehensive Cancer Network criteria. Twenty of 21 counseled participants appreciated being contacted. Relatives of 10 participants underwent cascade screening. Five of 16 eligible female BRCA1/2 variant carriers chose to undergo risk-reducing surgery, and 10 adhered to surveillance recommendations over the 30-month follow-up period. We recommend the return of results to population-based biobank participants; this approach could be viewed as a model for population-wide genetic testing. The genotype-first approach permits the identification of individuals at high risk who would not be identified by application of an approach based on personal and family histories only.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the European Union through the European Regional Development Fund (project no. 2014-2020.4.01.15-0012 GENTRANSMED), European Union Horizon 2020 (grant no. 810645, no. 654248), Estonian Research Council (PUT736 to N.T., PUT PRG555 to N.T., IUT20-60, PUT1660 to T.E., PUTJD817 to M.K., MOBERA15, RITA1/01-42-03).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Research Ethics Committee of the University of Tartu in 2016 (protocol no. 258/T-22 and no. 238/T-12)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll results generated in the study are provided in the manuscript and as Supplementary Tables.